The ERK1/2-RSK1/2-EphA2-GPRC5A signaling axis induced by cisplatin and carboplatin chemotherapy in serous ovarian carcinoma cell lines is closely correlated with acquired chemoresistance in cancer cells62. Here, RPS6KA1 is linked to ovarian serous carcinoma.